Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
Quanterix (NASDAQ: QTRX) reported Q1 2026 revenue of $36.4M (up 20% year‑over‑year) and ended the quarter with $102.6M in cash, cash equivalents, marketable securities, and restricted cash. GAAP gross margin was 42.7% and adjusted gross margin was 50.9%. Adjusted EBITDA loss narrowed to $9.8M. The company cites realized synergies from the Akoya acquisition, reiterated full‑year 2026 revenue guidance of $169–$174M, expects GAAP gross margin 41–45% and adjusted gross margin 49–53%, and anticipates cash‑flow breakeven in H2 2026 with year‑end cash near $100M and no debt.
Operationally, Quanterix announced collaborations with Tempus AI and Life Line Screening, PD‑BUILD participation, new assay and panel launches, and expects three clinical utility study completions plus an FDA 510(k) decision in H2 2026.
Lucent Diagnostics and Tempus AI (NASDAQ: TEM) announced a collaboration to integrate the LucentAD® Complete blood-based Alzheimer’s biomarker panel into Tempus Next care gap workflows and the Tempus clinical ordering platform.
The agreement makes LucentAD Complete available for neurologists to order via existing EHR integrations, aims to embed guideline-directed patient identification, and seeks to increase evaluation of patients eligible for approved Alzheimer’s treatments.
Quanterix (Nasdaq: QTRX) will report first quarter 2026 financial results and host a conference call on May 6, 2026 at 4:30 p.m. ET. A press release will be issued prior to the call after market close and posted on the company's website.
The live webcast will be accessible from the Investors Event Details page and an archived replay will be available for one year.
Quanterix (Nasdaq: QTRX) and PreludeDx announced that AidaBREAST is the first multi-omic assay to predict both 10-year locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
The validation included 922 HR+/HER2- patients with a median follow-up of ~10 years, and the test combines spatial proteomics on the Akoya PhenoImager HT platform with Opal chemistry plus targeted RNA sequencing. Findings will be presented at AACR Annual Meeting 2026 on April 21 at Quanterix booth 2028.
Quanterix (Nasdaq: QTRX) debuts its Content Innovation Engine at AACR 2026, integrating Akoya spatial biology with Quanterix SIMOA immunoassay expertise to accelerate translational and clinical spatial biology. New products and modules include the IO60 Spike-In Module, ADC high-plex content, PhenoCode Molecular Barcoding Kit (early access May 2026), and two ADC lung cancer panels available via Accelerator.
Quanterix will host live in-booth presentations April 20–21 and a large customer poster presence at AACR 2026.
Quanterix (NASDAQ: QTRX) announced its 2026 annual meeting of shareholders will be held virtually on June 9, 2026 at 10:00 AM ET. Stockholders of record as of April 14, 2026 may vote. The company set an April 6, 2026 deadline for shareholder proposals and director nominations.
Additional meeting details and proxy materials will be provided in the company's proxy statement.
Quanterix (NASDAQ: QTRX) reported Q4 2025 revenue of $43.9 million (+25% YoY) and full‑year 2025 revenue of $138.9 million (+1% YoY). GAAP gross margin declined to 45.7% in Q4. The company ended Q4 with $121.6 million in cash and expects cash‑flow breakeven in H2 2026 while guiding 2026 revenue to $169–174 million.
Operationally, Quanterix cited $74 million of cost savings from the Akoya transaction, 94% integration completion, a CMS reimbursement rate of $897 for LucentAD Complete, and a January 2026 510(k) submission for its Alzheimer’s blood test.
Lucent Diagnostics (NASDAQ: QTRX) partnered with Life Line Screening to offer Lucent’s non-invasive blood-based biomarker test nationally, with programs already underway in Florida, California, and Texas. Life Line Screening will use its mobile model to provide testing at community venues and share results to help primary care physicians enable earlier intervention.
Life Line Screening operates in the 48 contiguous states and hosts over 15,000 community events annually, supporting scalable access to testing for Alzheimer’s disease risk and MCI.
Quanterix (Nasdaq: QTRX) said its executive leadership will participate in two investor conferences in March 2026: the 46th Annual TD Cowen Healthcare Conference and the Leerink Global Healthcare Conference 2026. Fireside chats and one-on-one meetings are scheduled with webcasts available.
TD Cowen fireside chat: March 4, 2026 at 11:50 am ET. Leerink fireside chat: March 9, 2026 at 1:00 pm ET. According to the company, live and recorded webcasts will be available on the Investors section of the company website.
Quanterix (Nasdaq: QTRX) will report fourth quarter and full year 2025 financial results on March 2, 2026. The company will issue a press release after market close and host a conference call at 4:30 p.m. ET the same day to discuss the results.
Investors can join via dial-in (800-715-9871 or 646-307-1963, conference ID 7904928) or via live webcast on the company website; an archived replay will be available for one year.